Search results
FDA Approves Pivya, a New Treatment for UTIs in Women
Health via Yahoo News· 3 days agoIn a statement, the FDA cited three clinical trials that tested how well various Pivya dosing...
Akero Therapeutics (AKRO) SYMMETRY Study Under Fire in Class Action – AKRO Investors with...
Morningstar· 3 days agoSAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to submit their losses ...
Larimar's Friedreich's ataxia program free at last from FDA hold
FierceBiotech· 2 days agoLarimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a...
Earnings call: Vivos Therapeutics reports mixed Q1 results, aims for growth By Investing.com
Investing.com· 4 days agoVivos Therapeutics, a company specializing in the treatment of obstructive sleep apnea (OSA),...
FDA seeks AI tech to predict, detect Parkinson’s symptoms
MedTech Dive via Yahoo Finance· 2 days agoBy testing artificial intelligence and machine learning models, the agency hopes to come up with...
The 2030 Millionaire's Club: 3 Biotech Stocks to Buy Now
InvestorPlace· 4 hours agoWith the interest cuts coming up, it’s an ideal time to consider loading up on the top biotech...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 22 hours agoHence, BMY is banking on Opdivo and newer drugs like Reblozyl and Opdualag to drive growth in the...
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit
KTLA-TV Los Angeles· 7 days ago("Checkpoint" or the "Company") (NASDAQ: CKPT). Class Period: March 10, 2021 – December 15, 2023Lead Plaintiff Deadline: June 4, 2024...
FDA Withdraws Approval of FGFR Inhibitor for Bile Duct Cancer
MedPage Today· 3 days agoThe FDA has withdrawn the approval of infigratinib (Truseltiq) as a second-line treatment for...
Harnessing RNAi: Alnylam’s Path From Lab Discovery to Life-Changing Treatments
SciTechDaily· 2 hours agoAlnylam Pharmaceuticals, founded by MIT professors and former postdocs, has developed five FDA...